

**Prevalence of vitamin D is not associated with the COVID-19 epidemic in Europe. A critical update of the existing evidence.**

Dimitra Rafailia Bakaloudi <sup>a</sup>, Michail Chourdakis <sup>a\*</sup>

<sup>a</sup> Laboratory of Hygiene, Social & Preventive Medicine and Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Greece

**\*Corresponding Author**

Michail Chourdakis, School of Medicine, Faculty of Health Sciences, Aristotle University, University Campus, 54124, Thessaloniki, Greece; Phone: +30 2310 999035

Email: [mhourd@gapps.auth.gr](mailto:mhourd@gapps.auth.gr)

**Email addresses:** [dmpakalo@auth.gr](mailto:dmpakalo@auth.gr) (D.R. Bakaloudi), [mhourd@gapps.auth.gr](mailto:mhourd@gapps.auth.gr) (M. Chourdakis)

## ABSTRACT

**Background:** COVID-19 has emerged as a global pandemic, affecting nearly 104 million people worldwide as of February 4<sup>th</sup> 2021. In previous published studies, the association between the mean Vit D status of each country and COVID-19 infection rate, and mortality among the adult population in European countries was examined. The aim of this study was to re-examine the relationship between the Vit D status of each country and COVID-19 infection, recovery, and mortality using updated data and a different methodological approach.

**Methods:** Information only form the last decade on Vit D concentration/deficiency for each country was retrieved through literature search on PubMed<sup>®</sup> database. As of February, 4<sup>th</sup> 2021, COVID-19 infections and mortalities per one million population as well as total recoveries were extracted from the Worldometer website. The association between vitamin D deficiency and COVID-19 infection, recovery, and mortality were explored using correlation coefficients and scatterplots.

**Findings:** The prevalence of vitamin D deficiency among European countries ranged from 6.0 (Finland) to 75.5% (Turkey), with several countries facing more than 50% of vitamin D deficiency among their population. Non-significant correlations were observed between the number of COVID-19 infections ( $r=0.190$ ;  $p=0.374$ ), recoveries ( $r_s=0.317$ ,  $p=0.131$ ), and mortalities ( $r=0.129$ ;  $p=0.549$ ) per one million population, with the prevalence of vitamin D deficiency.

**Interpretation:** Prevalence of vitamin D deficiency was not significantly associated with either number of infections, recoveries or mortality rate of COVID-19 among European countries. Thus, it is an important parameter to be considered when implementing preventive measures to face COVID-19.

**Funding:** None

**Keywords:** Vitamin D, deficiency, COVID-19, infections, mortalities, Europe.

## ABBREVIATIONS

1M: One million; 25(OH)D: 25-hydroxyvitamin D<sub>3</sub>; ACE2: Angiotensin-Converting Enzyme 2; Ang (1-7): Angiotensin (1-7); ARS: Acute Respiratory Syndrome; COVID-19: Coronavirus disease 2019; ECTS: European Calcified Tissue Society; ICU: Intensive Care Unit; ISO: International Organization for Standardization; MasR: Mas Receptor; RAS: Renin - Angiotensin System; RCT: Randomized controlled trial; RICU: Respiratory Intermediate Care Unit; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus; UV: Ultraviolet; UVB: Ultraviolet B; Vit D: Vitamin D.

## INTRODUCTION

COVID-19 has become a global public health emergency, affecting more than 104 million people from 218 countries and territories<sup>1</sup> in less than a year since the very first outbreak in Wuhan, China.<sup>2</sup> As of February, 4<sup>th</sup> 2021, the lowest and highest number of confirmed cases were reported among Oceanic (50.336) and North American (31.357.026) continents respectively.<sup>1</sup> This substantial variation in the number of infections and as well as the severity and mortality of the disease can be accredited to several factors both at the state level as well as at an individual level. “State level” parameters include diverse factors, such as a country’s preparedness, actions of the governments, health infrastructure, timing of lockdown, rapid border closures, implementation of social distancing and socioeconomic status,<sup>3</sup> while the “individual level” includes the sociodemographic factors and other determinants of health status such as sex, age, chronic diseases, obesity, and malnutrition.<sup>4,5</sup>

It is well known that malnutrition constitutes a risk factor for increased mortality and morbidity of several diseases.<sup>6</sup> Protein and energy malnutrition, and other specific micronutrient deficiencies have been shown to manifest adverse effects in immunity and thereby exhibit poor prognosis of viral infections.<sup>7</sup> Regarding micronutrients, the association between vitamin D (Vit D) deficiency and various diseases’ prevalence and/or severity, such as autoimmune disorders, diabetes, skeletal diseases and acute respiratory tract infections have been adequately established in the past years.<sup>8,9</sup> However, evidence with regards to Vit D concentration and preventive and/or curative mechanisms of SARS-CoV-2 infection are limited<sup>10</sup> or present some controversies.<sup>11-13</sup> Recent studies have demonstrated the mechanisms for possible interactions between serum vitamin D concentration and rate of COVID-19 infections. Particularly, Vit D modulates the expression of angiotensin-converting enzyme 2 (ACE2), angiotensin (1-7) (Ang (1-7)), and mas receptor (MasR) axis and plays a crucial role in the protection against lung infection.<sup>14-16</sup> Thereby it acts as a renin-angiotensin system (RAS) inhibitor in treating COVID-19 patients with underlying comorbidities<sup>17,18</sup> and can lead to a weakening of the cytokine storm and the

Acute Respiratory Syndrome (ARS) risk among COVID-19 patients, but all this evidence lacking clinical validation<sup>19,20</sup>.

In three recently published studies the relationship between mean concentration of Vit D and number of cases and deaths of COVID-19/1M population in 20 European countries, negative correlations were reported.<sup>10,21,22</sup> In this study we aimed to re-examine the relationship between the status of Vit D and infections, recoveries, and mortalities of COVID-19 in European countries, using a bigger sample of countries and a different methodological approach.

## METHODS

### *Data sources and inclusion/exclusion criteria*

Information on COVID-19 infections, recoveries and mortalities, were retrieved from the Worldometer website, which provides real time statistics<sup>1</sup>. This source contains data derived directly from official government reports of individual countries and/or indirectly through reliable local media resources.

Data on the prevalence of Vit D deficiency among these countries were extracted by conducting a comprehensive electronic search in PubMed<sup>®</sup> database (up to February 6<sup>th</sup> 2021). An advanced search was performed at the level of title/abstract by using keywords such as “Vitamin D” or “25-hydroxyvitamin D<sub>3</sub>”, combined with “deficiency”, “prevalence” or “status” and the name of each European country. The final search string for each country and additional information about our search strategy are presented in **Supplementary Material**.

Inclusion criteria for our study were: a) Population-based studies that reported data in the last ten years; b) Studies reporting non-institutional adults (>18 years old); c) Studies defining Vit D deficiency as serum concentration <20 ng/ml or <50 nmol/l; d) Studies reporting Vit D deficiency prevalence of the sample population; e) European countries with population >1M; f) European countries in which >60.000 COVID-19 test/1M population were performed. Conference proceedings, editorials, commentaries, book

chapters/book reviews and studies confined to selective sample of community-dwelling people, such as pregnant women, menopausal women and patients with diagnosed illnesses were excluded. As a last step, out of the screened articles for each country, the prevalence of Vit D deficiency data was retrieved from the most recently published study, including the most representative sample for each country.

#### *Data extraction*

For each European country, information on COVID-19 infections, recoveries and mortalities per 1M population as of February, 4<sup>th</sup> 2021, were extracted from the Worldometer website.<sup>1</sup> From the selected articles reporting Vit D deficiency among these countries, name of the first author, published year, sample size, age range of the study population, mean Vit D concentration (nmol/L) and prevalence (%) of Vit D deficiency were retrieved. All data were extracted by one reviewer (DB) using a standardized excel form and were checked for accuracy by a second reviewer (MC).

#### *Data analysis*

The relationship between the prevalence of Vit D deficiency and variables, such as number of COVID-19 infections, recoveries and mortalities per 1M population were explored with Pearson ( $r$ ) or Spearman's rank ( $r_s$ ) correlation coefficients. Scatter plots were used to visually represent the correlations. All countries were represented by a 3-letter country code according to the ISO (International Organization for Standardization) 3.166, as per the Terminology Bulletin Country Names and the Country and Region Codes for Statistical Use maintained by the United Nations Statistics Divisions.<sup>23</sup> Both Pearson's and Spearman's correlation (2-tailed) tests were performed using the IBM SPSS<sup>®</sup> version 26-0 software.

## RESULTS

A total of 24 European countries, satisfying the inclusion/exclusion criteria were selected for the analysis<sup>24-47</sup> (**Table 1**). Countries excluded due to their limited population and/or lower number of COVID-19 tests were Andorra, Channel Islands, Faeroe Islands, Gibraltar, Iceland, Isle of Man, Liechtenstein Luxembourg, Malta, Monaco, Montenegro, San Marino, and Vatican city. Moreover, Albania, Belarus, Hungary, Latvia, Lithuania, Moldova, Netherlands, North Macedonia, Serbia, Slovakia, Spain, and Sweden were not part in our analysis because of the absence or the non-updated evidence regarding Vit D concentration, i.e. only data older than 10 years were available. The prevalence of Vit D deficiency ranged from 6.0-75.5% with the lowest and highest rates reported in Finland,<sup>32</sup> and Turkey<sup>45</sup> respectively. In 11 of the countries, the majority (>50%) of the adult population studied was Vit D deficient (i.e. <20 ng/ml or <50 nmol/l).<sup>25,27,31,34,39-41,43,45-47</sup> The size of study population which was used to retrieve data for the prevalence of Vit D deficiency varied from 280 (Slovenia)<sup>43</sup> to 74.235 subjects (Italy).<sup>37</sup>

As of February, 4<sup>th</sup> 2021, in regard to the total number of COVID-19 infections per 1M of the total population, Russia reported the lowest with 2.684/1M population, while the Czech Republic had the highest with 94.522/1M population infections. Regarding the COVID-19 mortalities per 1M population, the lowest number, was documented in Norway (105 deaths/1M), whereas the highest number, was reported in Belgium (1.826 deaths/1M). Regarding total recoveries the lowest number was reported in Switzerland (365.4/1M) whereas in Czech Republic the highest number of recoveries was observed (84.136/1M).

Cases of COVID-19 infections per 1M population displayed a non-significant, positive correlation ( $r=0.190$ ;  $p=0.374$ ) with the prevalence of Vit D deficiency (**Figure 1**).

As illustrated in **Figure 2**, COVID-19 mortality per 1M population was also not significantly correlated with the prevalence of Vit D deficiency ( $r=0.129$ ;  $p=0.549$ ).

As per the recovered COVID-19 cases per 1M population, similarly a non-significant correlation with the prevalence of Vit D deficiency can be observed in **Figure 3** ( $r_s=0.317$ ,  $p=0.131$ ). Moreover, the

correlation and the scatter plot of prevalence of Vit D deficiency and total recoveries per COVID-19 cases per country can be found in our **Supplementary Material**

We also examined the relationships between COVID-19 infections, recoveries and deaths with the mean vitamin D concentration of each country, as can be seen in the **Supplementary Material**, but again no significant correlation was found.

## DISCUSSION

Our analysis concluded that the prevalence of Vit D deficiency among the European population does not constitute a strong risk factor for COVID-19 neither infection, mortality nor recovery rates. However, these findings are not in line with outcomes of similar research works published recently.<sup>10,21,22</sup>

According to the outcomes of our study, in several of the European countries included in this analysis, more than 50% of the adult population was Vit D deficient, which constitutes a factor that should not be disregarded in the planning of public health preventive measures.<sup>25,27,31,34,39-41,43,45-47</sup> Factors that can influence Vit D concentration include the fluctuations of sunlight exposure among seasons,<sup>48</sup> especially the negligible amount of sunlight during winter and cloud covers during summer could potentially reduce the cutaneous synthesis of Vit D in some less south located countries,<sup>49,50</sup> as well as extend of clothing coverage and sunscreen use.<sup>51,52</sup> Furthermore, dietary sources of Vit D are limited and the obesity epidemic in the Europe, which is also related to poorer dietary choices, can worsen its deficiency.<sup>53</sup> Additionally, chronic diseases such as kidney disease,<sup>54,55</sup> liver disease,<sup>56</sup> malignancies<sup>57</sup> and genetic-epigenetic factors<sup>58</sup> can influence Vit D status.

The results of our analysis showed that the prevalence of Vit D deficiency is not significantly associated with COVID-19 infections ( $r=0.190$ ;  $p=0.374$ ), recoveries ( $r_s=0.312$ ,  $p=0.138$ ), and mortality rates ( $r=0.129$ ;  $p=0.549$ ). Nevertheless, the fact that our results differ from previous similar published studies<sup>10,21,22</sup> can be attributed to the alternative methodological approach, which we think is correct. In our study only prevalence of Vit D deficiency for each European country was used instead of mean Vit D

status for each country, a parameter which was used in those studies. A “mean” value cannot be representative of the Vit D status of a whole country because it is influenced by outliers and skewed populations. However, we have also conducted these analyses using updated data regarding Vit D mean concentration (only from the last decade) without finding any statistical significance (Supplementary Material). Therefore, we think that in the light of the most recent evidence of the COVID-19 pandemic, as well as by using updated information on Vit D deficiency prevalence for each included country, we can end up in more accurate conclusions.

Consequently, of course Vit D deficiency observed in several European countries is considered to be a crucial factor that should be frequently treated under medical supervision and not only by enhanced dietary intake<sup>59,60</sup> but abuse and/or misuse of Vit D supplementations, as a method to lower the risk for COVID-19 infection is not considered appropriate.

Numerous preprints with regard to Vit D status and its association with the COVID-19 infection, recovery and mortality can be found in relevant databases (e.g., medRxiv), but these preprints have not been peer-reviewed and therefore should not be used as clinical practice guidance; additionally, such fast-track publications constitute a common risk for low quality information and should not be considered of paramount importance during the COVID-19 pandemic. An editorial in *Lancet*, stands equally skeptical towards findings regarding Vit D supplementation in COVID-19 patients, until more solid data become available.<sup>61</sup> Moreover, also outside the scope of COVID-19, evidence regarding associations of Vit D with any outcome seems not to be convincing despite the great number of systematic reviews and meta-analyses that have been published.<sup>62</sup>

Although only 24 European countries satisfied our inclusion criteria, the analysis included a significant part of the European population.<sup>63</sup> Therefore, the results of our study could be generalized to most of the excluded European countries too. Moreover, along with the majority of high income countries, upper-middle income countries, such as Russia and Bosnia and Herzegovina were also included in the analysis,<sup>64</sup> reflecting the effect of economic status in the outcomes.

Among the limitations of our study is that the data on prevalence of Vit D deficiency of the countries included was not generated from national level surveys. Therefore, the very recently published studies (including data only from the last decade) with the most representative sample for each country's population were carefully selected for our analysis. As described in our Methods, screened studies were limited to adults ( $\geq 18$  years), as the severity of COVID-19 infections among children has been rather mild.<sup>65</sup> More detailed data regarding neither COVID-19 infection rates per age nor age distribution for each country was available, and therefore correlations for these subgroups could not be performed.

Governments should implement proper preventive measures to increase awareness among the populations on the risk of Vit D deficiency rather than on its role in during the COVID-19 pandemic. Vit D supplementation should be advised only for those belonging to a high risk group of deficiency, such as new-borns, toddlers, pregnant women, elderly as well as non-Western immigrants,<sup>66</sup> always under medical supervision and not as a preventive factor of COVID-19 infection. There might be several on-going randomized controlled trials (RCTs) examining the vitamin D supplementation in COVID-19 patients,<sup>67</sup> however until there are solid data available from well-designed RCTs that will allow us to take relevant clinical decisions, the supplementation of Vit D as a way to prevent infection or improve recovery cannot be evidence based suggested.

## CONCLUSION

Non-significant correlation was detected between the total number of COVID-19 infections per 1M population ( $r=0.190$ ;  $p=0.374$ ), recoveries ( $r_s=0.317$ ,  $p=0.131$ ) and mortality per 1M population ( $r=0.129$ ;  $p=0.549$ ) with respect to country-specific prevalence of Vit D deficiency among 24 European countries. The different methodological approach and the updated data regarding Vit D status of each country included, led to different results to previous published studies and this should be taken into account for the clinical practice.

## FUNDING

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## CONFLICTS OF INTEREST

All authors have no conflict of interest to disclose regarding the present study.

## AUTHOR CONTRIBUTIONS

Conceptualization and methodology: DB, MC

Data collection and validation: DB, MC

Data analysis: DB, MC

Writing-Original draft: DB, MC

Writing-Review and editing: DB, MC

## REFERENCES

1. Worldometer, COVID-19 Coronavirus Pandemic 2020. <https://www.worldometers.info/coronavirus/>
2. Zhu H, Wei L, Niu P. The novel coronavirus outbreak in Wuhan, China. *Global health research and policy* 2020; **5**(1): 1-3.
3. Chaudhry R, Dranitsaris G, Mubashir T, Bartoszko J, Riazi S. A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes. *EClinicalMedicine* 2020; **25**: 100464.
4. Fedele D, De Francesco A, Riso S, Collo A. Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic: An overview. *Nutrition (Burbank, Los Angeles County, Calif)* 2020; **81**: 111016-.
5. Clark A, Jit M, Warren-Gash C, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. *The Lancet Global Health* 2020; **8**(8): e1003-e17.
6. Söderström L, Rosenblad A, Adolfsson ET, Bergkvist L. Malnutrition is associated with increased mortality in older adults regardless of the cause of death. *British Journal of Nutrition* 2017; **117**(4): 532-40.
7. Jayawardena R, Sooriyaarachchi P, Chourdakis M, Jeewandara C, Ranasinghe P. Enhancing immunity in viral infections, with special emphasis on COVID-19: A review. *Diabetes Metab Syndr* 2020; **14**(4): 367-82.
8. Wacker M, Holick MF. Vitamin D—effects on skeletal and extraskelatal health and the need for supplementation. *Nutrients* 2013; **5**(1): 111-48.
9. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *Bmj* 2017; **356**: i6583.
10. Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. *Journal of Infection and Public Health* 2020; **13**(10): 1373-80.
11. Bergman P. The link between vitamin D and COVID-19: distinguishing facts from fiction. *J Intern Med* 2021; **289**(1): 131-3.
12. Murdaca G, Pioggia G, Negrini S. Vitamin D and Covid-19: an update on evidence and potential therapeutic implications. *Clinical and molecular allergy : CMA* 2020; **18**(1): 23.
13. Cereda E, Bogliolo L, Lobascio F, et al. Vitamin D supplementation and outcomes in coronavirus disease 2019 (COVID-19) patients from the outbreak area of Lombardy, Italy. *Nutrition (Burbank, Los Angeles County, Calif)* 2021; **82**: 111055-.
14. Cui C, Xu P, Li G, et al. Vitamin D receptor activation regulates microglia polarization and oxidative stress in spontaneously hypertensive rats and angiotensin II-exposed microglial cells: role of renin-angiotensin system. *Redox biology* 2019; **26**: 101295.
15. Li Y, Zeng Z, Cao Y, et al. Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF- $\kappa$ B signaling pathways. *Scientific reports* 2016; **6**: 27911.
16. Rhodes JM, Subramanian S, Laird E, Griffin G, Kenny RA. Perspective: Vitamin D deficiency and COVID-19 severity – plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis. *J Intern Med* 2021; **289**(1): 97-115.
17. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin–angiotensin system and blood pressure. *The Journal of steroid biochemistry and molecular biology* 2004; **89**: 387-92.
18. Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? *Eur Heart J* 2020; **41**(19): 1801-3.

19. Carpagnano GE, Di Lecce V, Quaranta VN, et al. Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19. *Journal of endocrinological investigation* 2020: 1-7.
20. Daneshkhan A, Agrawal V, Eshein A, Subramanian H, Roy HK, Backman V. Evidence for possible association of vitamin D status with cytokine storm and unregulated inflammation in COVID-19 patients. *Aging Clinical and Experimental Research* 2020; **32**(10): 2141-58.
21. Singh S, Kaur R, Singh RK. Revisiting the role of vitamin D levels in the prevention of COVID-19 infection and mortality in European countries post infections peak. *Aging clinical and experimental research* 2020; **32**(8): 1609-12.
22. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. *Aging Clin Exp Res* 2020; **32**(7): 1195-8.
23. ISO 3166 Country Codes. The International Standard for country codes and codes for their subdivisions: International Organization for Standardization.
24. Elmadfa I, Meyer A, Wottawa D, Wagner K, Hasenegger V. Vitamin D Intake and Status in Austria and Its Effects on Some Health Indicators. 2018.
25. Hoge A, Donneau AF, Streel S, et al. Vitamin D deficiency is common among adults in Wallonia (Belgium, 51°30' North): findings from the Nutrition, Environment and Cardio-Vascular Health study. *Nutrition research (New York, NY)* 2015; **35**(8): 716-25.
26. Sokolovic S, Alimanovic-Alagic R, Džananovic L, Cavaljuga S, Beslic N, Ferhatbegovic-Opankovic E. Vitamin D status in Bosnia and Herzegovina: the cross-sectional epidemiological analysis. *Osteoporos Int* 2017; **28**(3): 1021-5.
27. Borissova AM, Shinkov A, Vlahov J, et al. Vitamin D status in Bulgaria--winter data. *Arch Osteoporos* 2013; **8**: 133.
28. Colić Barić I, Keser I, Bituh M, et al. Vitamin D status and prevalence of inadequacy in Croatian population. Book of Abstracts of 4th International congress of nutritionists; 2016; 2016. p. 97.
29. Mayer O, Jr., Filipovský J, Seidlerová J, et al. The association between low 25-hydroxyvitamin D and increased aortic stiffness. *Journal of human hypertension* 2012; **26**(11): 650-5.
30. Cashman KD, Dowling KG, Škrabáková Z, et al. Standardizing serum 25-hydroxyvitamin D data from four Nordic population samples using the Vitamin D Standardization Program protocols: Shedding new light on vitamin D status in Nordic individuals. *Scandinavian Journal of Clinical and Laboratory Investigation* 2015; **75**(7): 549-61.
31. Pludowski P, Grant WB, Bhattoa HP, et al. Vitamin D Status in Central Europe. *International Journal of Endocrinology* 2014; **2014**: 589587.
32. Adebayo FA, Itkonen ST, Lilja E, et al. Prevalence and determinants of vitamin D deficiency and insufficiency among three immigrant groups in Finland: evidence from a population-based study using standardised 25-hydroxyvitamin D data. *Public Health Nutr* 2020; **23**(7): 1254-65.
33. Souberbielle JC, Massart C, Brailly-Tabard S, Cavalier E, Chanson P. Prevalence and determinants of vitamin D deficiency in healthy French adults: the VARIETE study. *Endocrine* 2016; **53**(2): 543-50.
34. Rabenberg M, Scheidt-Nave C, Busch MA, Rieckmann N, Hintzpeter B, Mensink GBM. Vitamin D status among adults in Germany--results from the German Health Interview and Examination Survey for Adults (DEGS1). *BMC public health* 2015; **15**: 641-.
35. Dimakopoulos I, Magriplis E, Mitsopoulou AV, et al. Association of serum vitamin D status with dietary intake and sun exposure in adults. *Clin Nutr ESPEN* 2019; **34**: 23-31.
36. Cashman KD, Kiely M, Kinsella M, et al. Evaluation of Vitamin D Standardization Program protocols for standardizing serum 25-hydroxyvitamin D data: a case study of the program's potential for national nutrition and health surveys. *The American journal of clinical nutrition* 2013; **97**(6): 1235-42.
37. Giuliani S, Barbieri V, Di Pierro AM, et al. LC-MS/MS based 25(OH)D status in a large Southern European outpatient cohort: gender- and age-specific differences. *Eur J Nutr* 2019; **58**(6): 2511-20.

38. Petrenya N, Lamberg-Allardt C, Melhus M, Broderstad AR, Brustad M. Vitamin D status in a multi-ethnic population of northern Norway: the SAMINOR 2 Clinical Survey. *Public Health Nutr* 2020; **23**(7): 1186-200.
39. Płudowski P, Ducki C, Konstantynowicz J, Jaworski M. Vitamin D status in Poland. *Pol Arch Med Wewn* 2016; **126**(7-8): 530-9.
40. Duarte C, Carvalheiro H, Rodrigues AM, et al. Prevalence of vitamin D deficiency and its predictors in the Portuguese population: a nationwide population-based study. *Arch Osteoporos* 2020; **15**(1): 36.
41. Niculescu DA, Capatina CAM, Dusceac R, Carageorgheopol A, Ghemigian A, Poiana C. Seasonal variation of serum vitamin D levels in Romania. *Arch Osteoporos* 2017; **12**(1): 113.
42. Karonova T, Andreeva A, Nikitina I, et al. Prevalence of Vitamin D deficiency in the North-West region of Russia: A cross-sectional study. *J Steroid Biochem Mol Biol* 2016; **164**: 230-4.
43. Hribar M, Hristov H, Gregorič M, et al. Nutrihealth Study: Seasonal Variation in Vitamin D Status Among the Slovenian Adult and Elderly Population. *Nutrients* 2020; **12**(6): 1838.
44. Sakem B, Nock C, Stanga Z, et al. Serum concentrations of 25-hydroxyvitamin D and immunoglobulins in an older Swiss cohort: results of the Senior Labor Study. *BMC medicine* 2013; **11**: 176.
45. Öztürk ZA, Gol M, Türkbeyler İ H. Prevalence of vitamin D deficiency in otherwise healthy individuals between the ages of 18 and 90 years in southeast Turkey. *Wiener klinische Wochenschrift* 2017; **129**(21-22): 854-5.
46. Aspell N, Laird E, Healy M, Shannon T, Lawlor B, O'Sullivan M. The Prevalence and Determinants of Vitamin D Status in Community-Dwelling Older Adults: Results from the English Longitudinal Study of Ageing (ELSA). *Nutrients* 2019; **11**(6): 1253.
47. Shchubelka K. Vitamin D status in adults and children in Transcarpathia, Ukraine in 2019. *BMC Nutr* 2020; **6**(1): 48-.
48. Schramm S, Lahner H, Jöckel K-H, et al. Impact of season and different vitamin D thresholds on prevalence of vitamin D deficiency in epidemiological cohorts—a note of caution. *Endocrine* 2017; **56**(3): 658-66.
49. Webb A, Kift R, Durkin M, et al. The role of sunlight exposure in determining the vitamin D status of the UK white adult population. *British Journal of Dermatology* 2010; **163**(5): 1050-5.
50. Mendes MM, Darling AL, Hart KH, Morse S, Murphy RJ, Lanham-New SA. Impact of high latitude, urban living and ethnicity on 25-hydroxyvitamin D status: A need for multidisciplinary action? *The Journal of Steroid Biochemistry and Molecular Biology* 2019; **188**: 95-102.
51. Mishal AA. Effects of different dress styles on vitamin D levels in healthy young Jordanian women. *Osteoporos Int* 2001; **12**(11): 931-5.
52. Neale RE, Khan SR, Lucas RM, Waterhouse M, Whiteman DC, Olsen CM. The effect of sunscreen on vitamin D: a review. *The British journal of dermatology* 2019; **181**(5): 907-15.
53. Snijder MB, van Dam RM, Visser M, et al. Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. *The Journal of Clinical Endocrinology & Metabolism* 2005; **90**(7): 4119-23.
54. Li M, Li Y. Prevalence and influencing factors of vitamin D deficiency in chronic kidney disease: A cross-sectional study. *International journal of clinical pharmacology and therapeutics* 2020; **58**(11): 595-600.
55. El Din US, Fayed A, El Nokeety MM, Abdulazim DO, Salem MM. Vitamin-D deficiency is encountered in almost all egyptian stage 3-5 chronic kidney disease patients in spite of the sunny weather. *Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia* 2019; **30**(6): 1389-97.
56. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. *Digestive diseases and sciences* 2010; **55**(9): 2624-8.

57. Gupta D, Vashi PG, Trukova K, Lis CG, Lammersfeld CA. Prevalence of serum vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature. *Exp Ther Med* 2011; **2**(2): 181-93.
58. Bahrami A, Sadeghnia HR, Tabatabaeizadeh SA, et al. Genetic and epigenetic factors influencing vitamin D status. *Journal of cellular physiology* 2018; **233**(5): 4033-43.
59. Kasapidou E, Oikonomidou A, Chourdakis M. Vitamin D status among Mediterranean regions. *Hippokratia* 2018; **22**(4): 191.
60. van Schoor N, Lips P. Worldwide vitamin D status. *Vitamin D: Elsevier*; 2018: 15-40.
61. The Lancet D, Endocrinology. Vitamin D and COVID-19: why the controversy? *The Lancet Diabetes & Endocrinology* 2021; **9**(2): 53.
62. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JPA. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. *BMJ : British Medical Journal* 2014; **348**: g2035.
63. WHO Coronavirus Disease (COVID-19) Dashboard. 2020. <https://covid19.who.int/> (accessed 24 December 2020).
64. Schlienger JL, Monnier L. Mediterranean diets and diabetes prevention: Time for evidence. *Medecine des Maladies Metaboliques* 2020; **14**(7): 626-31.
65. Brodin P. Why is COVID-19 so mild in children? *Acta Paediatrica* 2020; **109**(6): 1082-3.
66. Lips P, Cashman KD, Lamberg-Allardt C, et al. Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. *European Journal of Endocrinology* 2019; **180**(4): P23-P54.
67. Annweiler C, Beaudenon M, Gautier J, et al. COvid-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial. *Trials* 2020; **21**(1): 1031.

## FIGURE LEGENDS

**Figure 1:** Scatter diagram of the prevalence of vitamin D deficiency against COVID-19 infections, as of February, 4th 2021.

**Figure 2:** Scatter diagram of the prevalence of vitamin D deficiency against COVID-19 deaths, as of February, 4th 2021.

**Figure 3:** Scatter diagram of the prevalence of vitamin D deficiency against total recovered COVID-19 cases, as of February, 4th 2021.

## TABLE LEGENDS

**Table 1:** The prevalence of vitamin D deficiency among 24 European countries.

**Supplementary Table 1:** Search terms of PubMed<sup>®</sup> database.

### Supplementary figures:

**Supplementary Figure 1:** Scatter diagram of the prevalence of vitamin D deficiency against total recoveries per COVID-19 cases, as of February, 4th 2021.

**Supplementary Figure 2A:** Scatter diagram of the mean vitamin D against COVID-19 infections, as of February, 4th 2021

**Supplementary Figure 2B:** Scatter diagram of the mean vitamin D against COVID-19 deaths, as of February, 4th 2021.

**Supplementary Figure 2C:** Scatter diagram of the mean vitamin D against total COVID-19 recovery cases, as of February, 4th 2021.


**Supplementary Figure 2D:** Scatter diagram of the mean vitamin D against total recoveries per COVID-19 cases, as of February, 4th 2021

**Table 1:** The prevalence of vitamin D deficiency among 24 European countries.

| <b>Country</b>            | <b>Author, Year</b>          | <b>Sample size<br/>(M/ F)</b> | <b>Age<br/>(years)</b> | <b>Mean Vitamin D<br/>(nmol/L)</b> | <b>Prevalence of<br/>vitamin D<br/>deficiency* (%)</b> |
|---------------------------|------------------------------|-------------------------------|------------------------|------------------------------------|--|
| Austria                   | Elmadfa et al.,<br>2017      | 541<br>(220/321)              | 18-80                  | No info                            | 48.0   |
| Belgium                   | Hoge et al.,<br>2015         | 697<br>(378-319)              | 21-65                  | 49.8                               | 51.1   |
| Bosnia and<br>Herzegovina | Sokolovic et<br>al., 2016    | 1830<br>(No info)             | >18                    | No info                            | 24.3   |
| Bulgaria                  | Borissova et<br>al., 2013    | 2016<br>(948/1068)            | 20-80                  | 38.75                              | 54.5   |
| Croatia                   | Baric et al.<br>2016         | 791<br>(131/660)              | 45.5 <sup>1</sup>      | 54.4                               | 46.1   |
| Czech Republic            | Mayer et al.,<br>2012        | 560<br>(239/321)              | 25-75                  | 62.5                               | 24.4   |
| Denmark                   | Cashman et al.,<br>2015      | 3409<br>(1892/1517)           | 19-72                  | 65.0                               | 23.6   |
| Estonia                   | Pludowski et<br>al., 2014    | 367<br>(167/200)              | 25-70                  | 43.7                               | 73.0   |
| Finland                   | Adebayo et<br>al., 2020      | 798<br>(No info)              | 30-64                  | 64.0                               | 6.0  |
| France                    | Souberbielle et<br>al., 2016 | 892<br>(463/429)              | 18-89                  | 60.0                               | 34.6   |
| Germany                   | Rabenberg et<br>al., 2015    | 6995<br>(3360/3635)           | 18-79                  | 45.6                               | 61.5   |


|                |                           |                        |        |         |       |
|----------------|---------------------------|------------------------|--------|---------|-------|
| Greece         | Dimakopoulos et al., 2019 | 1084<br>(410/674)      | ≥18    | 41.8    | 32.4  |
| Ireland        | Cashman et al., 2013      | 1118<br>(No info)      | 18-84  | 56.4    | 43.7  |
| Italy          | Giuliani et al., 2018     | 74235<br>(18811/55424) | 18-104 | 68.5    | 33.3  |
| Norway         | Petrenya et al., 2020     | 4465<br>(2041/2424)    | 40-69  | 64.0    | 24.7  |
| Poland         | Pludowski et al., 2016    | 5775<br>(1311/4464)    | 16-90  | 45.0    | 65.8  |
| Portugal       | Duarte et al., 2020       | 3092<br>(1907/1995)    | ≥18    | 42.15   | 66.6  |
| Romania        | Niculescu et al., 2017    | 14052<br>(1705/12347)  | >21    | 49.5    | 52.0  |
| Russia         | Karonova et al., 2016     | 1544<br>(205/1294)     | 18-75  | 54.8    | 45.7  |
| Slovenia       | Hribar et al., 2020       | 280<br>(128/152)       | 18-74  | 50.7    | 60.7  |
| Switzerland    | Sakem et al., 2013        | 1291<br>(600/691)      | >60    | No info | 39.2  |
| Turkey         | Öztürk et al., 2017       | 1161 (798/363)         | 18-90  | 70.0    | 75.5  |
| United Kingdom | Aspell et al., 2019       | 6004<br>(2713/3291)    | >60    | 48.7    | 55.3  |
| Ukraine        | Shchubelka et al., 2020   | 1639 (NA)              | 18-82  | 22.67   | 51.74 |

\*Serum 25-hydroxyvitamin D<sub>3</sub> concentration <20 ng/ml or <50 nmol/l; F: Female; M: Male;  
Mean age of the participants




**Figure 1:** Scatter diagram of the prevalence of vitamin D deficiency against COVID-19 infections, as of February, 4<sup>th</sup> 2021.

*AUT: Austria, BEL: Belgium, BIH: Bosnia and Herzegovina, BGR: Bulgaria, HRV: Croatia, CZE: Czech Republic, DNK: Denmark, EST: Estonia, FIN: Finland, FRA: France, DEU: Germany, GRC: Greece, IRL: Ireland, ITA: Italy, NOR: Norway, POL: Poland, PRT: Portugal, ROU: Romania, RUS: Russia, SVN: Slovenia, CHE: Switzerland, TUR: Turkey, GBR: United Kingdom, UKR: Ukraine.*



**Figure 2:** Scatter diagram of the prevalence of vitamin D deficiency against COVID-19 deaths, as of February, 4<sup>th</sup> 2021.

*AUT Austria, BEL: Belgium, BIH: Bosnia and Herzegovina, BGR: Bulgaria, HRV: Croatia, CZE: Czech Republic, DNK: Denmark, EST: Estonia, FIN: Finland, FRA: France, DEU: Germany, GRC: Greece, IRL: Ireland, ITA: Italy, NOR: Norway, POL: Poland, PRT: Portugal, ROU: Romania, RUS: Russia, SVN: Slovenia, CHE: Switzerland, TUR: Turkey, GBR: United Kingdom, UKR: Ukraine.*



**Figure 3:** Scatter diagram of the prevalence of vitamin D deficiency against total recovered COVID-19 cases, as of February, 4<sup>th</sup> 2021.

AUT Austria, BEL: Belgium, BIH: Bosnia and Herzegovina, BGR: Bulgaria, HRV: Croatia, CZE: Czech Republic, DNK: Denmark, EST: Estonia, FIN: Finland, FRA: France, DEU: Germany, GRC: Greece, IRL: Ireland, ITA: Italy, NOR: Norway, POL: Poland, PRT: Portugal, ROU: Romania, RUS: Russia, SVN: Slovenia, CHE: Switzerland, TUR: Turkey, GBR: United Kingdom, UKR: Ukraine.